Long-term inhibition of Rho kinase suppresses intimal thickening in autologous vein grafts in rabbits

Journal of Vascular Surgery

Volumn 43, Issue 6, 2006, Pages 1249-1256

  Furuyama, Tadashi ^a   Komori, Kimihiro ^b   Shimokawa, Hiroaki ^c   Matsumoto, Yasuharu ^a   Uwatoku, Toyokazu ^a   Hirano, Katsuya ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FASUDIL; HYDROXYFASUDIL; RHO KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GRAFT FAILURE; INTERNAL JUGULAR VEIN; LONG TERM CARE; MALE; NONHUMAN; PHARMACODYNAMICS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RABBIT; RANDOMIZATION; SMOOTH MUSCLE FIBER; TREATMENT DURATION; VASCULAR SMOOTH MUSCLE; VEIN DISEASE; VEIN GRAFT; VEIN INTIMA PROLIFERATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANALYSIS OF VARIANCE; ANIMALS; CAROTID ARTERY, COMMON; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JUGULAR VEINS; MALE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RABBITS; RANDOM ALLOCATION; TUNICA INTIMA;

EID: 33744734643     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2006.02.035     Document Type: Article

References (40)

1. Belkin M., Knox J., Donaldson M.C., Mannick J.A., and Whittemore A.D. Infrainguinal arterial reconstruction with nonreversed greater saphenous vein. J Vasc Surg 24 (1996) 957-962
2. Donaldson M.C., Mannick J.A., and Whittemore A.D. Causes of primary graft failure after in situ saphenous vein bypass grafting. J Vasc Surg 15 (1992) 113-120
3. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease. pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
4. Davies M.G., and Hagen P.O. Pathophysiology of intimal hyperplasia. Br J Surg 81 (1994) 1254-1269
5. Davies M.G., and Hagen P.O. Pathobiology of vein graft failure. Eur J Vasc Endovasc Surg 9 (1995) 7-18
6. Somlyo A.P., and Somlyo A.V. Signal transduction and regulation in smooth muscle. Nature 372 (1994) 231-236
7. 2+ sensitivity in vascular smooth muscle. J Smooth Muscle Res 40 (2004) 219-236
8. Kimura K., Ito M., Amano M., Chihara K., Fukata Y., Nakafuku M., et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273 (1996) 245-248
9. Amano M., Fukata Y., and Kaibuchi K. Regulation and function of Rho-associated kinase. Exp Cell Res 261 (2000) 44-51
10. Hall A. Rho GTPases and the actin cytoskeleton. Science 279 (1998) 509-514
11. Shimokawa H., and Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25 (2005) 1767-1775
12. Schmitz A.A.P., Govek E.E., Bottner B., and Van Aelst L. Rho GTPases. signaling, migration, and invasion. Exp Cell Res 261 (2000) 1-12
13. Lacal J.C. Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling. FEBS Lett 410 (1997) 73-77
14. Eto Y., Shimokawa H., Hiroki J., Morishige K., Kandabashi T., Matsumoto Y., et al. Gene transfer of dominant negative Rho-kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol 278 (2000) H1744-H1750
15. Morishige K., Shimokawa H., Eto Y., Kandabashi T., Miyata K., Matsumoto Y., et al. Adenovirus-mediated transfer of dominant-negative Rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol 21 (2001) 548-554
16. Shimokawa H., Seto M., Katsumata N., Amano M., Kozai T., Yamawaki T., et al. Rho-kinase-mediated pathway induced enhanced myosin light chain phosphorylations in swine model of coronary artery spasm. Cardiovasc Res 43 (1999) 1138-1141
17. Shimokawa H., Morishige K., Miyata K., Kandabashi T., Eto Y., Ikegaki I., et al. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 51 (2001) 169-177
18. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39 (2002) 319-327
19. Kandabashi T., Shimokawa H., Mukai Y., Matoba T., Kunihiro I., Morikawa K., et al. Involvement of Rho-kinase in agonist-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 22 (2002) 243-248
20. Matsumoto Y., Uwatoku T., Oi K., Abe K., Hattori T., Morishige K., et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries. involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 24 (2004) 181-186
21. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Circ Res 93 (2003) 767-775
22. Okazaki J., Komori K., Kawasaki K., Eguchi D., Ishida M., and Sugimachi K. L-Arginine inhibits smooth muscle cell proliferation of graft intimal thickness in hypercholesterolemic rabbits. Cardiovasc Res 36 (1997) 429-436
23. Nakashima K., Nishimura J., Hirano K., Ibayashi S., Fujishima M., and Kanaide H. Hydroxyfasudil, an active metabolite of fasudil hydrochloride, relaxes the rabbit basilar artery by disinhibition of myosin light chain phosphatase. J Cereb Blood Flow Metab 21 (2001) 876-885
24. Morinaga K., Eguchi H., Miyazaki T., Okadome K., and Sugimachi K. Development and regression of intimal thickening of arterially transplanted autologous vein grafts in dogs. J Vasc Surg 5 (1987) 719-730
25. Komori K., Gloviczki P., Bourchier R.G., Miller V.M., and Vanhoutte P.M. Endothelium-dependent vasorelaxations in response to aggregating platelets are impaired in reversed vein grafts. J Vasc Surg 12 (1990) 139-147
26. Yamanouchi D., Banno H., Nakayama M., Sugimoto M., Fujita H., Kobayashi M., et al. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. J Vasc Surg 42 (2005) 757-764
27. Leville C.D., Osipov V.O., Jean-Claude J.M., Seabrook G.R., Towne J.B., and Cambria R.A. All-trans-retinoic acid decreases cell proliferation and increase apoptosis in an animal model of vein bypass grafting. Surgery 128 (2000) 178-184
28. Masumoto A., Mohri M., Shimokawa H., Urakami L., Usui M., and Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospasm angina. Circulation 105 (2002) 1545-1547
29. Ozaki Y., Keane D., and Serruys P.W. Progression and regression of coronary stenosis in the long-term follow-up of vasospastic angina. Circulation 92 (1995) 2446-2456
30. Ishii T., Okadome K., Komori K., Odashiro T., and Sugumachi K. Natural course of endothelium-dependent and -independent responses in autogenous femoral vein grafted into the arterial circulation of the dog. Circ Res 72 (1993) 1004-1010
31. Itoh H., Komori K., Funahashi S., Okadome K., and Sugumachi K. Intimal hyperplasia of experimental autologous vein graft in hyperlipidemic rabbits with poor runoff. Atherosclerosis 110 (1994) 259-270
32. Zwolak R.M., Adams M.C., and Clowes A.W. Kinetics of vein graft hyperplasia. association with tangential stress. J Vasc Surg 5 (1987) 126-136
33. Shibata R., Kai H., Seki Y., Kato S., Morimatsu M., Kaibuchi K., et al. Role of Rho-associated kinase in neointima formation after vascular injury. Circulation 3 (1997) 894-899
34. Sawada N., Itoh H., Ueyama K., Yamashita J., Doi K., Chun T.H., et al. Inhibition of Rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101 (2000) 2030-2033
35. Ai S., Kuzuya M., Koike T., Asai T., Kanda S., Maeda K., et al. Rho-Rho kinase is involved in smooth muscle cell migration through myosin light chain phosphorylation-dependent and independent pathways. Atherosclerosis 155 (2001) 321-327
36. Negoro N., Hoshiga M., Seto M., Kohbayashi E., Ii M., Fukui R., et al. The kinase inhibitor fasudil (HA-1077) reduced intimal hyperplasia through inhibiting and enhancing cell loss of vascular smooth muscle cells. Biochem Biophys Res Commun 262 (1999) 211-215
37. Seasholtz T.M., Majumdar M., Kaplan D.D., and Brown J.H. Rho and Rho kinase mediated thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 84 (1999) 1186-1193
38. Kalra M., and Miller V.M. Early remodeling of saphenous vein grafts. proliferation, migration and apoptosis of adventitial and medial cells occur simultaneously with changes in graft diameter and blood flow. J Vasc Res 37 (2000) 576-584
39. Davies M.G., Fulton G.J., Svendsen E., Svendson E., and Hagen P.O. Time course of the regression of intimal hyperplasia in experimental vein grafts. Cardiovasc Pathol 8 (1999) 161-168
40. Pearce J.D., Li Jing, Edwards M.S., English W.P., and Geary R.L. Differential effects of Rho-kinase inhibition on artery wall mass and remodeling. J Vasc Surg 39 (2004) 223-228